Acrux presentation at Hidden Gems in Lifesciences Forum
Filed with ASX · · 14 pages · English
In the deck
Earlier from Acrux
- Launch of Dapsone 5%, Gel in the United States
- Investor Presentation Half Year Accounts
- Appendix 4D and Half Year Accounts
- Appendix 4C and Activities Statement
- Address of Chair and CEO to AGM
Later from Acrux
- RDTI funding facility secured
- Acrux presentation to Bioshares, 18th Biotech Summit
- Quarterly Activities Report and Appendix 4C - June 2024
- FDA Approval received for Dapsone Gel, 7.5%
- Appendix 4E and FY24 Full Year Statutory Accounts
Follow Acrux into a list and get an email when it puts out news.
Follow Acrux